Thomas Burt, a venture capitalist, has become a non-executive director at Redx Pharma Plc, representing the Sofinnova Crossover Fund, a recent investor. Mr Burt has been a partner in the fund since its inception in 2017. Prior to this, he was a research analyst at Peel Hunt and earlier, a member of the healthcare investment banking team at Piper Jaffray & Co. He holds a doctorate in engineering from University College London, UK.
Redx Pharma announced the appointment on 5 August 2020.
Copyright 2020 Evernow Publishing Ltd